echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CDE intends to identify Hengrui CDK4/6 inhibitors and Junshi anti-PD-1 for breakthrough therapy

    CDE intends to identify Hengrui CDK4/6 inhibitors and Junshi anti-PD-1 for breakthrough therapy

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the official website of CDE showed that Hengrui SHR6390 tablets and Junshitraprizumab were planned to be included in breakthrough therapy by CDE.


    Hengrui: SHR6390 tablets

    SHR6390 tablet is a class 1 new drug developed by Hengrui.


    On December 24 last year, Hengrui announced that the primary endpoint of the Phase III clinical study (SHR6390-III-301) for this indication met the pre-specified superiority standard.


    In addition, Hengrui has also registered SHR6390 in the country for the treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma in combination with anti-PD-1 antibody SHR1210, and the treatment of patients with malignant melanoma of the head and neck mucosa who have failed standard treatment with CDK4 amplification.


    PharmaGo

    At present, Pfizer and Qilu's pipercillil capsules and Eli Lilly's Abbeceil tablets have been approved for marketing.


    Junshi: Teriprolizumab

    Junshi Bio-PD1 Teriplimumab Injection is planned to be included in the breakthrough therapy indication as the first-line treatment of advanced mucosal melanoma.


    It is worth noting that the first approved indication for Teriplizumab is the treatment of unresectable or metastatic melanoma after the failure of previous systemic treatments.


    In August 2019, Junshi announced the results of an open-label phase IB clinical trial of teriprizumab combined with the anti-angiogenic drug axitinib for the treatment of advanced mucosal melanoma.


    At present, the phase III clinical trial (IND) application of teriprizumab combined with axitinib for the first-line treatment of patients with mucosal melanoma has been approved by the FDA.


    Mucosal melanoma is one of the subtypes of melanoma.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.